Discussion of Diagnosis and Treatment of Diabetic Peripheral Neuropathy
WALTHAM, Mass.--(BUSINESS WIRE)-- Shai N. Gozani, M.D., Ph.D, President and Chief Executive Officer of NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, was interviewed live on the TuDiabetes.org website yesterday, March 6, 2014. TuDiabetes.org is a community of people touched by diabetes and is a program of the Diabetes Hands Foundation.
During the live interview, Dr. Gozani provided answers to a range of questions from the TuDiabetes.org community about the diagnosis and treatment of diabetic peripheral neuropathy or DPN. Additionally, he discussed a range of available tests such as the company's DPNCheck® device, a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy, as well as various treatment options including the company's SENSUS™ Pain Management System for treating chronic intractable pain such as painful diabetic neuropathy.
To view the interview in its entirety, please visit the following link: http://youtu.be/JPJ7BSA66Hk
About NeuroMetrix
NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The Company is presently focused on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company also markets the DPNCheck® device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit http://www.DPNCheck.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
